natgillin/translations-raw huggingface dataset:
Occasionally hardened minor local swellings (0.5 - 2.0 cm) were observed which disappeared within 21 days after vaccination. 
Občasno so zasledili manjše otekline v obliki zatrdlin (0,5 do 2,0 cm), ki so minile v 21 dneh po cepljenju.
Light liquid paraffin, Polysorbate 80, Sorbitan oleate, phosphate buffered aqueous solution 6.2 Incompatibilities 
Redko tekoči parafin, polisorbat 80, sorbitan oleat, vodna raztopina s sulfatnim pufrom 6.2 Inkompatibilnosti
If you are accidentally injected with this product, seek prompt medical advice even if only a very small amount is injected and take the package insert with you. 
Če vam je bil ta izdelek nenamerno injiciran, se takoj posvetujte z zdravnikom, čeprav je bila injicirana le majhna količina, in mu pokažite navodila za uporabo.
a) the administration of the veterinary medicinal product to animals will interfere with the implementation of national programmes for the diagnosis, control and eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals b) the disease to which the veterinary medicinal product is intended to confer immunity is largely absent from the territory. 
a) bi uporaba zdravila za uporabo v veterinarski medicini ovirala izvajanje nacionalnih programov za diagnozo, nadzor ali zatiranje živalskih bolezni ali da bi povzročila težave pri zagotavljanju odsotnosti okuženosti pri živih živalih ali živilih ali drugih proizvodih, pridobljenih iz zdravljenih živali.
Marketing authorisation holder and manufacturer: 
Imetnik dovoljenja za promet z zdravilom in izdelovalec:
Accidental injection is dangerous - see package insert before use. 
Nenamerno injiciranje je nevarno - pred uporabo preberite priloženo navodilo.
Any unused veterinary medicinal product or waste material derived from such veterinary medicinal products should be disposed of in accordance with the local requirements. 
Vsako neporabljeno zdravilo ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z lokalnimi predpisi.
Store and transport at 2 - 8°C. 
Shranjujte in prevažajte pri temperaturi 2-8 ºC.
SPECIAL STORAGE CONDITIONS Store and transport at 2 - 8°C. 
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte in prevažajte pri temperaturi 2-8 °C.
Under field conditions passive immunity is transferred during lay for 43 weeks after the last vaccination of broiler breeders, resulting in a duration of passive immunity in broilers of at least 14 days after hatching. 
V razmerah na farmi se pasivna imunost prenaša v obdobju valjenja 43 tednov po zadnjem cepljenju brojlerskih matičnih jat, tako da traja pasivna imunost brojlerjev najmanj 14 dni po izvalitvi.
• Sorbitan oleate (E 494), Potassium dihydrogen phosphate (E 340), Disodium hydrogen phosphate (E 339) and Potassium chloride (E 508) are approved as additives in foodstuffs for human consumption and therefore covered by Annex II of Council Regulation (EEC) No. 2377/90 for substances with an E- number1 (with the exception of preservatives listed in part C of Annex III 
• Sorbitan oleat (E 494), kalijev dihidrogenfosfat (E 340), natrijev dihidrogenfosfat (E 339) in kalijev klorid (E 508) so odobreni prehrambeni dodatki, zato jih ureja Dodatek II Uredbe Sveta (EGS) št.
MANUFACTURER'S BATCH NUMBER Lot: …… 
IZDELOVALČEVA ŠTEVILKA Serija:………
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Per dose of 0.25 ml: 
NAVEDBA ZDRAVILNE(IH) UČINKOVIN(E) IN DRUGE(IH) SESTAVIN V odmerku po 0,25 ml:
Mineral hydrocarbons, low to high viscosity including microcristalline waxes, approximately C10-C60; aliphatic, branched aliphatic and alicyclic compounds. 
Mineralni ogljikovodiki, majhne do velike viskoznosti: mikrokristalni voski, približno C10-C60; alifatske, razvejane alifatske in aliciklične spojine vse živalske vrste, namenjene za prehrano ljudi
Nobilis OR inac emulsion for injection for chickens 
Nobilis OR inac, emulzija za injiciranje za piščance
• The adjuvants and excipients listed are included in Annex II of Council Regulation (EEC) No 
• Naštete dodatke in pomožne snovi vsebuje Dodatek II Uredbe Sveta (EGS) št. 2377/90.
CONTENTS BY WEIGHT, BY VOLUME OR NUMBER OF DOSES 250 ml (1000 doses) 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ODMERKOV 250 ml (1000 odmerkov)
Allow vaccine to reach room temperature (15-25°C) before using the vaccine. 
Cepivo pred uporabo ogrejte na sobno temperaturo (15-25 °C).
No other undesirable effects have been observed after administration of a double dose when compared with a single dose of vaccine. 
Dvojni odmerek v primerjavi z enojnim odmerkom cepiva ni povzročil dodatnih neželenih učinkov.
NAME OF THE VETERINARY MEDICINAL PRODUCT Nobilis OR inac emulsion for injection for chickens 
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI Nobilis OR inac, emulzija za injiciranje za piščance
The vaccination scheme consists of two injections with a dose of 0.25 ml, administered subcutaneously in the neck or intramuscularly in the breast. 
Shema cepljenja je dve injekciji z odmerkom po 0,25 ml subkutano na vratu ali intramuskularno v prsni predel.
STATEMENT OF ACTIVE AND OTHER SUBSTANCES 
NAVEDBA ZDRAVILNE UČIKOVINE IN DRUGIH SNOVI
All food producing species 
vse živalske vrste, namenjene za prehrano ljudi
Pharmacologically active substance Animal Species 
Farmakološko aktivna snov
For animal treatment only -to be supplied only on veterinary prescription. 
Samo za živali - oskrba le na podlagi veterinarskega recepta.
The product contains the inactivated whole cells of Ornithobacterium rhinotracheale serotype A, strain B3263/91 mixed with an oil adjuvant. 
Izdelek vsebuje inaktivirane celice bakterije Ornithobacterium rhinotracheale, serotip A, sev B3263/91 v obliki mešanice z oljnim adjuvansom.
1 PET vial with 250 ml (1000 doses) 1 PET vial with 500 ml (2000 doses) 
1 viala iz polietilen tereftalata (PET) po 250 ml (1000 odmerkov) 1 viala iz polietilen tereftalata (PET) po 500 ml (2000 odmerkov)
Accidental self-injection is dangerous - see package insert 
Nenamerno injiciranje je nevarno - preberite priloženo navodilo.
EU Number EU/2/02/036/001 (250 ml) EU/2/02/036/002 (500 ml) 
Številka EU EU/2/02/036/001 (250 ml) EU/2/02/036/002 (500 ml)
Shelf life after first opening: Use immediately after opening 
Rok uporabnosti po prvem odpiranju vsebnika: uporabite takoj po odpiranju.
4.4 Special warnings 
4.4 Posebna opozorila
ACTIVE SUBSTANCE(S) Inactivated whole cell suspension of O. rhinotracheale Light liquid paraffin 
KOLIČINA ZDRAVILNE UČINKOVINE Inaktivirana suspenzija celic bakterije O. rhinotracheale Redko tekoči parafin
NAME OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE IN THE EEA, IF DIFFERENT 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER IMETNIKA DOVOLJENJA ZA PROIZVODNJO ZDRAVILA, ODGOVORNEGA ZA SPROŠČANJE SERIJ V EGP, ČE STA RAZLIČNA
C. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO SAFE AND EFFECTIVE USE 
C. POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM TER OMEJITVE GLEDE VARNE IN UČINKOVITE UPORABE
Inactivated whole cell suspension of Ornithobacterium rhinotracheale serotype A strain B3263/91 1 x 107 cells * 
Inaktivirana suspenzija celic bakterije Ornithobacterium rhinotracheale, serotip A, sev B3263/91 1 x 107 celic*
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE IN THE EEA 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER IMETNIKA DOVOLJENJA ZA PROIZVODNJO ZDRAVILA, ODGOVORNEGA ZA SPROSTITEV SERIJ V EGP
METHOD AND ROUTE(S) OF ADMINISTRATION Subcutaneous injection in the neck or intramuscular injection in the breast of one dose of 0.25 ml. 
NAČIN IN POT(I) UPORABE En odmerek po 0,25 ml subkutano na vratu ali intramuskularno v prsni predel
6.5 Nature and composition of immediate packaging Carton box with one Polyethylene Terephthalate (PET) vial of 250 ml (1000 doses) or 500 ml (2000 doses), closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap. 6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products 
Zloženka z eno vialo iz polietilen tereftalata (PET) po 250 ml (1000 odmerkov) ali po 500 ml (2000 odmerkov), zaprto z zamaškom iz sintetične gume in aluminijasto zaporko s šifro.
MARKETING AUTHORISATION NUMBER(S) EU/2/02/036/001-002 
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/02/036/001-002
Name and address of the manufacturer responsible for batch release 
Ime in naslov izdelovalca zdravila, odgovornega za sproščanje serije
MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE 
IZDELOVALEC(IZDELOVALCI) BIOLOŠKE ZDRAVILNE UČINKOVINE (ZDRAVILNIH UČINKOVIN) IN IMETNIK(I) DOVOLJENJ(A) ZA IZDELAVO ZDRAVILA, ODGOVOREN(ODGOVORNI) ZA SPROŠČANJE SERIJE
4.2 Indications for use, specifying the target species For passive immunisation of broilers induced by active immunisation of female broiler breeders to reduce infection with Ornithobacterium rhinotracheale serotype A when this agent is involved. 
4.2 Indikacije za uporabo pri ciljnih živalskih vrstah Pasivna imunizacija brojlerjev z aktivno imunizacijo živali ženskega spola v brojlerskih matičnih jatah za zmanjšanje okužbe z Ornithobacterium rhinotracheale serotipa A, kadar je ta bakterija prisotna.
CONTRAINDICATIONS Do not use for birds in lay 
KONTRAINDIKACIJE Ne uporabite v obdobju valjenja.
MARKETING AUTHORISATION NUMBER(S) EU/2/02/036/001 (250 ml) 
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/02/036/001 (250 ml)
For passive immunisation of broilers induced by active immunisation of female broiler breeders to reduce infection with Ornithobacterium rhinotracheale serotype A when this agent is involved. 
Pasivna imunizacija brojlerjev z aktivno imunizacijo živali ženskega spola v brojlerskih matičnih jatah za zmanjšanje okužbe z Ornithobacterium rhinotracheale serotipa A, kadar je ta bakterija prisotna.
Inactivated whole cell suspension of Ornithobacterium rhinotracheale serotype A, strain B3263/91 1 x 107 cells * * inducing a mean titre in the chickens of the potency test of at least 11.2 (log2). 
Inaktivirana suspenzija celic bakterije Ornithobacterium rhinotracheale, serotip A, sev B3263/91 1 x 107 celic* *pri preizkusu učinkovitosti pri piščancih spodbudi nastanek srednjega titra, ki je najmanj 11,2 (log2) Dodatek
* inducing a mean titre in the chickens of the potency test of at least 11.2 (log2). 
*pri preizkusu učinkovitosti pri piščancih spodbudi nastanek srednjega titra, ki je najmanj 11,2 (log2) Redko tekoči parafin: 107,21 mg
The vaccine is to stimulate active immunity in broiler breeders in order to provide passive immunity to the progeny against Ornithobacterium rhinotracheale serotype A. 
Cepivo uporabljamo za spodbujanje aktivne imunosti pri brojlerskih matičnih jatah, da bi vzbudili pasivno imunost potomcev proti Ornithobacterium rhinotracheale, serotip A.
Do not use in birds in lay. 
Ne uporabljajte v obdobju valjenja.
THE WORDS "KEEP OUT OF THE REACH AND SIGHT OF CHILDREN" Keep out of the reach and sight of children 
BESEDILO ''ZDRAVILO SHRANJUJTE NEDOSEGLJIVO OTROKOM'' Zdravilo shranjujte nedosegljivo otrokom.
injection of one dose of 0.25 ml. 
POTI UPORABE En odmerek po 0,25 ml s.c. ali i.m.
Adjuvant 
INDIKACIJE
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALEC(IZDELOVALCI) BIOLOŠKE ZDRAVILNE UČINKOVINE (ZDRAVILNIH UČINKOVIN) IN IMETNIK(I) DOVOLJENJ(A) ZA IZDELAVO ZDRAVILA, ODGOVOREN(ODGOVORNI) ZA SPROŠČANJE SERIJE
THE WORDS "FOR ANIMAL TREATMENT ONLY" For animal treatment only. 
BESEDILO SAMO ZA ŽIVALI Samo za živali.
QUALITATIVE AND QUANTITATIVE COMPOSITION Per dose of 0.25 ml: 
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Once broached: Use immediately 
Rok uporabnosti po prvem odpiranju vsebnika: Uporabite takoj po pripravi.
Subcutaneous injection in the neck or intramuscular injection in the breast of the chicken. 
Enkratni odmerek po 0,25 ml. Subkutano na vratu ali intramuskularno v prsni predel.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY ORUSE 
POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM TER OMEJITVE GLEDE OSKRBE IN UPORABE
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION Single dose of 0.25 ml. 
ODMERKI ZA POSAMEZNE ŽIVALSKE VRSTE TER POT(I) IN NAČIN UPORABE ZDRAVILA
Active substance 
Pomožne snovi
Pack size blister (PVC/PE/PVDC/alu) 
Velikost pakiranja pretisni omot (PVC/PE/PVDC/alu)
30 mg Film-coated tablet Oral use 
30 mg Filmsko obložena tableta
This overview was last updated in 03-2018. 
Pregled je bil nazadnje posodobljen 03-2018.
Further information on Invirase can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Več informacij o zdravilu Invirase je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
These studies measured the viral load after 48 weeks. 
V teh študijah so izmerili virusno breme po 48 tednih.
What measures are being taken to ensure the safe and effective use of Invirase? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Invirase?
The European Medicines Agency decided that Invirase's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Invirase večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Invirase received a marketing authorisation valid throughout the EU on 4 October 1996. 
Za zdravilo Invirase je bilo 4. oktobra 1996 izdano dovoljenje za promet, veljavno po vsej EU.
Invirase was found effective in the treatment of HIV infection in six main studies involving a total of 1,576 patients. 
Zdravilo Invirase se je pokazalo kot učinkovito pri zdravljenju okužbe z virusom HIV v šestih glavnih študijah, v katere je bilo skupno vključenih 1 576 bolnikov.
Invirase is available as capsules (200 mg) and tablets (500 mg). 
Zdravilo Invirase je na voljo v obliki kapsul (200 mg) in tablet (500 mg).
What is Invirase and what is it used for? 
Kaj je zdravilo Invirase in za kaj se uporablja?
It must not be used in patients who have had arrhythmia (unstable heartbeat). 
Ne sme se uporabljati pri bolnikih, ki so imeli aritmijo (nestabilen srčni utrip).
• medicines that could cause QT prolongation or PR prolongation (another type of heart activity alteration); 
• zdravila, ki bi lahko povzročila podaljšanje intervala QT ali PR (druga vrsta spremembe delovanja srca);
What benefits of Invirase have been shown in studies? 
Kakšne koristi zdravila Invirase so se pokazale v študijah?
Why is Invirase authorised in the EU? 
Zakaj je bilo zdravilo Invirase odobreno v EU?
As for all medicines, data on the use of Invirase are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Invirase stalno spremljajo.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Invirase have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Invirase upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
It must also not be used in patients who are taking any of the following medicines which could cause harmful side effects if taken with Invirase: 
Prav tako se ne sme uporabljati pri bolnikih, ki jemljejo katero od naslednjih zdravil, saj bi lahko ta ob sočasnem jemanju z zdravilom Invirase povzročila škodljive neželene učinke:
This allows effective treatment while avoiding a higher dose of saquinavir. 
To prispeva k učinkovitemu zdravljenju in hkrati omogoča, da bolniku ni treba prejemati višjega odmerka sakvinavirja.
Side effects reported with Invirase are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Invirase, se skrbno ovrednotijo in po potrebi se lahko sprejmejo ukrepi za zaščito bolnikov.
An overview of Invirase and why it is authorised in the EU 
Pregled zdravila Invirase in zakaj je odobreno v EU
• ergot alkaloids, such as ergotamine, dihydroergotamine, ergonovine and methylergonovine (used to treat migraine headache); 
• ergot alkaloidi, kot so ergotamin, dihidroergotamin, ergonovin in metilergonovin (uporabljajo se za zdravljenje migrenskega glavobola);
Invirase is an antiviral medicine used to treat adults infected with the human immunodeficiency virus type 1 (HIV 1), a virus that causes acquired immune deficiency syndrome (AIDS). 
Invirase je protivirusno zdravilo, ki se uporablja za zdravljenje odraslih, okuženih z virusom humane imunske pomanjkljivosti tipa 1 (HIV 1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
Two further studies involving 656 patients compared Invirase with indinavir or lopinavir (other HIV medicines). 
V dveh drugih študijah s 656 bolniki so zdravilo Invirase primerjali z indinavirjem ali lopinavirjem (drugima zdraviloma za zdravljenje okužbe z virusom HIV).
• rifampicin (used to treat tuberculosis); 
• rifampicin (uporablja se za zdravljenje tuberkuloze);
When the enzyme is blocked, the virus does not reproduce normally, slowing down the spread of infection. 
Ko je encim zavrt, se virus ne more več normalno razmnoževati, kar zmanjša hitrost širjenja okužbe.
Other information about Invirase 
Druge informacije o zdravilu Invirase
What are the risks associated with Invirase? 
Kakšna tveganja so povezana z zdravilom Invirase?
Invirase must not be used in patients who have severe problems with their liver, QT prolongation (an alteration of the electrical activity of the heart), abnormal levels of electrolytes in the blood (especially low potassium levels), bradycardia (slow heart rate) or heart failure (when the heart does not work as well as it should). 
Zdravilo Invirase se ne sme uporabljati pri bolnikih, ki imajo hude težave z jetri, podaljšanje intervala QT (sprememba električnega delovanja srca), nenormalne ravni elektrolitov v krvi (zlasti nizko raven kalija), bradikardijo (upočasnjen srčni ritem) ali srčno popuščanje (pri katerem srce ne deluje tako dobro, kot bi moralo).
It slows the breakdown of saquinavir, increasing the levels of saquinavir in the blood. 
Upočasnjuje hitrost razgradnje sakvinavirja in s tem povečuje njegovo raven v krvi.
Ritonavir is another protease inhibitor that is used as a ‘booster'. 
Ritonavir je drug zaviralec proteaze, ki se uporablja kot „ojačevalec“.
For more information about using Invirase, see the package leaflet or contact a doctor or pharmacist. 
Za več informacij glede uporabe zdravila Invirase glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
It blocks protease, an enzyme involved in the reproduction of HIV. 
Zavira proteazo, tj. encim, ki sodeluje pri razmnoževanju virusa HIV.
Invirase can only be obtained with a prescription and treatment should be started by a doctor who has experience in the treatment of HIV infection. 
Predpisovanje in izdaja zdravila Invirase je le na recept, zdravljenje z njim pa mora uvesti zdravnik, ki ima izkušnje z zdravljenjem okužb z virusom HIV.
Invirase does not cure HIV infection or AIDS, but it may hold off the damage to the immune system and the development of infections and diseases associated with AIDS. 
Zdravilo Invirase ne ozdravi okužbe z virusom HIV ali aidsa, lahko pa upočasni slabšanje imunskega sistema ter razvoj okužb in bolezni, povezanih z aidsom.
Invirase should only be used in combination with ritonavir (another antiviral medicine) and other antiviral medicines. 
Zdravilo Invirase se uporablja samo v kombinaciji z ritonavirjem (drugim protivirusnim zdravilom) in drugimi protivirusnimi zdravili.
• simvastatin, lovastatin (used to lower cholesterol); 
• simvastatin, lovastatin (uporabljata se za zniževanje holesterola);
The most common side effects when taking Invirase in combination with ritonavir (which may affect more than 1 patient in 10) are diarrhoea, nausea (feeling sick), increased levels of liver enzymes, cholesterol and triglycerides (a type of fat) in the blood, and decreased levels of platelets in the blood (components that help blood to clot). 
Najpogostejši neželeni učinki pri jemanju zdravila Invirase v kombinaciji z ritonavirjem (ki se lahko pojavijo pri več kot 1 bolniku od 10) so driska, navzea (siljenje na bruhanje), zvišane ravni jetrnih encimov, holesterola in trigliceridov (vrste maščobe) v krvi ter znižane ravni trombocitov v krvi (celic, ki pomagajo pri strjevanju krvi).
In the first four studies, Invirase in combination with other HIV medicines, but without ritonavir, reduced the viral load and improved the immune system. 
V prvih štirih študijah je zdravilo Invirase v kombinaciji z drugimi zdravili za zdravljenje okužbe z virusom HIV, vendar brez ritonavirja, zmanjšalo virusno breme in okrepilo imunski sistem.
Invirase, taken in combination with other HIV medicines, reduces the viral load (the amount of HIV in the blood) and keeps it at a low level. 
Zdravilo Invirase v kombinaciji z drugimi zdravili za zdravljenje okužbe z virusom HIV zmanjša virusno breme (količino virusa HIV v krvi) in ga ohranja na nizki ravni.
For patients already taking HIV medicines, the recommended dose of Invirase is 1,000 mg with 100 mg ritonavir twice daily. 
Za bolnike, ki že jemljejo zdravila za zdravljenje okužbe z virusom HIV, je priporočeni odmerek zdravila Invirase 1 000 mg s 100 mg ritonavirja dvakrat na dan.
The medicines were given in combination with ritonavir and two other HIV medicines. 
Zdravila so dajali v kombinaciji z ritonavirjem in dvema drugima zdraviloma za zdravljenje okužbe z virusom HIV.
• lurasidone, quetiapine (used to treat psychiatric illness such as schizophrenia). 
• lurazidon, kvetiapin (uporabljata se za zdravljenje duševnih motenj, kot je shizofrenija).
After 7 days, the recommended dose of Invirase is 1,000 mg twice daily with ritonavir 100 mg twice daily in combination with other HIV medicines. 
Po sedmih dneh znaša priporočeni odmerek zdravila Invirase 1 000 mg dvakrat na dan skupaj s 100 mg ritonavirja dvakrat na dan v kombinaciji z drugimi zdravili za zdravljenje okužbe z virusom HIV.
• midazolam taken by mouth, triazolam (used to relieve anxiety or difficulty sleeping); 
• midazolam za peroralno uporabo, triazolam (uporabljata se za lajšanje tesnobnosti ali težav s spanjem);
Invirase contains the active substance saquinavir. 
Zdravilo Invirase vsebuje zdravilno učinkovino sakvinavir.
For patients who are not taking HIV medicines, Invirase is started at 500 mg twice daily with ritonavir 100 mg twice daily for the first 7 days of treatment, given in combination with other HIV medicines. 
Pri bolnikih, ki zdravil za zdravljenje okužbe z virusom HIV še ne jemljejo, se zdravilo Invirase uvede v odmerku 500 mg dvakrat na dan s 100 mg ritonavirja dvakrat na dan v prvih sedmih dneh zdravljenja, pri čemer se daje v kombinaciji z drugimi zdravili.
Invirase in combination with ritonavir was as effective as indinavir but more effective than lopinavir in reducing the viral load to less than 50 copies/ml. 
V študijah, v katerih so zdravilo Invirase proučevali v kombinaciji z ritonavirjem, je bilo zdravilo Invirase pri zmanjševanju virusnega bremena na manj kot 50 kopij/ml enako učinkovito kot indinavir in učinkovitejše od lopinavirja.
The active substance in Invirase, saquinavir, is a ‘protease inhibitor'. 
Učinkovina v zdravilu Invirase, sakvinavir, je zaviralec proteaze.
How is Invirase used? 
Kako se zdravilo Invirase uporablja?
For the full list of side effects of Invirase, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Invirase, glejte navodilo za uporabo.
How does Invirase work? 
Kako zdravilo Invirase deluje?
Main outcomes of this study are presented in this table: 
Glavni izidi te študije so predstavljeni v tej preglednici:
You may become sleepy and could lose consciousness. 
Lahko postanete zaspani in zgubite zavest.